Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Delanaye

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Diabetes & Metabolism|November 18, 2017
Renal outcomes with dipeptidyl peptidase-4 inhibitorsA J Scheen, P Delanaye
Diabetes & Metabolism|February 4, 2017
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEA J Scheen, P Delanaye
Revue Medicale De Liege|May 28, 2015
[Rituximab (MabThera): a new therapy for ANCA vasculitis]C von Frenckell, P Delanaye
Revue Medicale De Liege|March 8, 2021
[SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice]A J Scheen, P Delanaye
Revue Medicale De Liege|January 14, 2022
[SGLT2 inhibitors and RAAS blockers : similarities, differences and complementarity]A J Scheen, P Delanaye
Revue Medicale De Liege|January 12, 2023
[EMPA-KIDNEY: empagliflozin in chronic kidney disease]P Delanaye, A J Scheen
Revue Medicale De Liege|May 12, 2005
[News about phosphorus metabolism]P Delanaye, J M Krzesinski
Revue Medicale De Liege|March 24, 2015
[Evaluation of glomerular filtration rate in 2014]P Delanaye, J-M Krzesinski
Revue Medicale De Liege|July 29, 2014
[How to manage chronic kidney disease in the elderly?]J M Krzesinski, P Delanaye
Revue Medicale De Liege|September 19, 2000
[Prevention strategies against malaria]P Delanaye, D Nkoghe, J Demonty
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Diabetes & Metabolism|November 18, 2017
Renal outcomes with dipeptidyl peptidase-4 inhibitorsA J Scheen, P Delanaye
Diabetes & Metabolism|February 4, 2017
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEA J Scheen, P Delanaye
Revue Medicale De Liege|May 28, 2015
[Rituximab (MabThera): a new therapy for ANCA vasculitis]C von Frenckell, P Delanaye
Revue Medicale De Liege|March 8, 2021
[SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice]A J Scheen, P Delanaye
Revue Medicale De Liege|January 14, 2022
[SGLT2 inhibitors and RAAS blockers : similarities, differences and complementarity]A J Scheen, P Delanaye
Revue Medicale De Liege|January 12, 2023
[EMPA-KIDNEY: empagliflozin in chronic kidney disease]P Delanaye, A J Scheen
Revue Medicale De Liege|May 12, 2005
[News about phosphorus metabolism]P Delanaye, J M Krzesinski
Revue Medicale De Liege|March 24, 2015
[Evaluation of glomerular filtration rate in 2014]P Delanaye, J-M Krzesinski
Revue Medicale De Liege|July 29, 2014
[How to manage chronic kidney disease in the elderly?]J M Krzesinski, P Delanaye
Revue Medicale De Liege|September 19, 2000
[Prevention strategies against malaria]P Delanaye, D Nkoghe, J Demonty
Pageof 6